<DOC>
	<DOCNO>NCT00057304</DOCNO>
	<brief_summary>The objective study determine dose ( ) Ro 205-2349 , compare placebo , efficacious , safe tolerable improve glycemic control patient type 2 diabetes . Doses 2 5 mg/day study .</brief_summary>
	<brief_title>Study Determine Efficacy , Safety , Tolerability &amp; Pharmacokinetics RO 205-2349 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Age 35 75 Type 2 diabetes longer 3 month HbA1c ( glycosylated hemoglobin A1c ) great 7.0 % screen FPG ( fast plasma glucose ) great 126 mg/dL screen BMI ( body mass index ) less 40 kg/square meter Type I diabetes Type 2 diabetes patient currently treat insulin Type 2 diabetes patient currently previously treat Actos , Avandia Rezulin FPG ( fast plasma glucose ) great 270 mg/dL baseline Impaired liver kidney function Triglycerides great 600 mg/dL Uncontrolled hypertension Pregnant lactate woman Women use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>